Haemonetics Corporation (HAE) — Analyst outlook / Analyst consensus target is. Based on 20 analyst ratings, the consensus is bullish — 10 Buy, 10 Hold.
The consensus price target is $86.60 (low: $80.00, high: $94.00), representing an upside of 43.2% from the current price $60.48.
Analysts estimate Earnings Per Share (EPS) of $2.43 and revenue of $1.36B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $2.32 vs est $2.43 (missed -4.7%). 2025: actual $3.31 vs est $4.54 (missed -27.2%). Analyst accuracy: 79%.
HAE Stock — 12-Month Price Forecast
$86.60
▲ +43.19% Upside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for Haemonetics Corporation, the average price target is $86.60, with a high forecast of $94.00, and a low forecast of $80.00.
The average price target represents a +43.19% change from the last price of $60.48.
Highest Price Target
$94.00
Average Price Target
$86.60
Lowest Price Target
$80.00
HAE Analyst Ratings
Buy
Based on 20 analysts giving stock ratings to Haemonetics Corporation in the past 3 months
EPS Estimates — HAE
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $2.32
vs Est $2.43
▼ 5.0% off
2025
Actual $3.31
vs Est $4.54
▼ 37.3% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — HAE
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $1.309B
vs Est $1.361B
▼ 4.0% off
2025
Actual $1.361B
vs Est $1.360B
▲ 0.1% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
